EMA Recommends Granting a Marketing Authorisation for Catumaxomab By Ogkologos - November 12, 2024 389 0 Facebook Twitter Google+ Pinterest WhatsApp It is intended for the intraperitoneal treatment of malignant ascites Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Revumenib for Relapsed or Refractory Acute Myeloid Leukaemia with a Susceptible NPM1 Mutation Antitumour Activity of Patritumab Deruxtecan in Heavily Pretreated Patients with Active Brain Metastases of Breast Cancer and NSCLC EMA Recommends Extension of Indications for Sugemalimab MOST POPULAR Celebrating 20 Years of Cancer.Net: How We’ve Worked to Empower People... May 3, 2022 Early cancer diagnosis and COVID-19: unpicking the impact of the pandemic December 20, 2022 Corgi Named Dolly Didn’t Win At Westminster, But Is A Champion... February 12, 2020 Research with integrity – referencing work is way more than just... May 3, 2023 Load more HOT NEWS New Research Discovers How Scalp Cooling Helps Chemo Patients Keep Their... Nivolumab Injections Could Make Treatment Easier for More People with Cancer What Are Biosimilars in Cancer Treatment? Elections 2021: What the results mean for people with cancer
